Reference
[1] N. Krugliak Cleveland, J. Torres, D.T. Rubin, What Does Disease
Progression Look Like in Ulcerative Colitis, and How Might It Be
Prevented?, Gastroenterology 162(5) (2022) 1396-1408.
[2] S. Jiang, D. Chen, C. Ma, H. Liu, S. Huang, J. Zhang,
Establishing a novel inflammatory bowel disease prediction model based
on gene markers identified from single nucleotide variants of the
intestinal microbiota, iMeta 1(3) (2022) e40.
[3] H. Nakase, N. Sato, N. Mizuno, Y. Ikawa, The influence of
cytokines on the complex pathology of ulcerative colitis, Autoimmun Rev
21(3) (2022) 103017.
[4] X. Han, S. Ding, H. Jiang, G. Liu, Roles of Macrophages in the
Development and Treatment of Gut Inflammation, Frontiers in Cell and
Developmental Biology 9 (2021).
[5] N. Tatiya-Aphiradee, W. Chatuphonprasert, K. Jarukamjorn, Immune
response and inflammatory pathway of ulcerative colitis, J Basic Clin
Physiol Pharmacol 30(1) (2018) 1-10.
[6] F.E.M. Ali, I.M. Ibrahim, O.M. Ghogar, E.K. Abd-Alhameed, H.S.
Althagafy, E.H.M. Hassanein, Therapeutic interventions target the NLRP3
inflammasome in ulcerative colitis: Comprehensive study, World J
Gastroenterol 29(6) (2023) 1026-1053.
[7] S.E. Corcoran, R. Halai, M.A. Cooper, Pharmacological Inhibition
of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome
with MCC950, Pharmacological Reviews 73(3) (2021) 968-1000.
[8] Y. Zhen, H. Zhang, NLRP3 Inflammasome and Inflammatory Bowel
Disease, Front Immunol 10 (2019) 276.
[9] X. Yao, C. Zhang, Y. Xing, G. Xue, Q. Zhang, F. Pan, G. Wu, Y.
Hu, Q. Guo, A. Lu, X. Zhang, R. Zhou, Z. Tian, B. Zeng, H. Wei, W.
Strober, L. Zhao, G. Meng, Remodelling of the gut microbiota by
hyperactive NLRP3 induces regulatory T cells to maintain homeostasis,
Nat Commun 8(1) (2017) 1896.
[10] S. Zhu, S. Ding, P. Wang, Z. Wei, W. Pan, N.W. Palm, Y. Yang,
H. Yu, H.B. Li, G. Wang, X. Lei, M.R. de Zoete, J. Zhao, Y. Zheng, H.
Chen, Y. Zhao, K.A. Jurado, N. Feng, L. Shan, Y. Kluger, J. Lu, C.
Abraham, E. Fikrig, H.B. Greenberg, R.A. Flavell, Nlrp9b inflammasome
restricts rotavirus infection in intestinal epithelial cells, Nature
546(7660) (2017) 667-670.
[11] M.H. Pan, Y.F. Su, X.J. Liu, S.Q. Xiang, Y.X. Ding, Q. Li,
Identification of Forsythia suspensa (Thunb.) Vahl in different harvest
periods using intelligent sensory technologies, HPLC characteristic
fingerprint coupled with chemometrics, Phytochem Anal 33(3) (2022)
490-501.
[12] C. Wang, C. Ma, K. Fu, Y. Liu, L. Gong, C. Peng, Y. Li,
Hepatoprotective effect of phillygenin on carbon tetrachloride-induced
liver fibrosis and its effects on short chain fatty acid and bile acid
metabolism, J Ethnopharmacol 296 (2022) 115478.
[13] Y. Lin, P. Yang, Phillygenin inhibits the inflammation and
apoptosis of pulmonary epithelial cells by activating PPARgamma
signaling via downregulation of MMP8, Mol Med Rep 24(5) (2021).
[14] H. Li, M. Chen, Z. Yang, Q. Wang, J. Wang, D. Jin, X. Yang, F.
Chen, X. Zhou, K. Luo, Phillygenin, a MELK Inhibitor, Inhibits Cell
Survival and Epithelial-Mesenchymal Transition in Pancreatic Cancer
Cells, Onco Targets Ther 13 (2020) 2833-2842.
[15] W. Zhou, X. Yan, Y. Zhai, H. Liu, L. Guan, Y. Qiao, J. Jiang,
L. Peng, Phillygenin ameliorates nonalcoholic fatty liver disease via
TFEB-mediated lysosome biogenesis and lipophagy, Phytomedicine 103
(2022) 154235.
[16] X. Ding, D. Lu, J. Fan, A natural product phillygenin
suppresses osteosarcoma growth and metastasis by regulating the
SHP-1/JAK2/STAT3 signaling, Biosci Biotechnol Biochem 85(2) (2021)
307-314.
[17] N. Hu, C. Wang, X. Dai, M. Zhou, L. Gong, L. Yu, C. Peng, Y.
Li, Phillygenin inhibits LPS-induced activation and inflammation of LX2
cells by TLR4/MyD88/NF-kappaB signaling pathway, J Ethnopharmacol 248
(2020) 112361.
[18] S. Wu, Y. Zhang, Y. Zhang, L. Chen, X. Xu, Y. Dang, X. Ti,
Phillygenin regulates proliferation and apoptosis of non-small cell lung
cancer through by AMPK/ERK/NF-kappaB axis, Pharmazie 75(10) (2020)
512-515.
[19] R. Ungaro, S. Mehandru, P.B. Allen, L. Peyrin-Biroulet, J.F.
Colombel, Ulcerative colitis, Lancet 389(10080) (2017) 1756-1770.
[20] T. Kobayashi, B. Siegmund, C. Le Berre, S.C. Wei, M. Ferrante,
B. Shen, C.N. Bernstein, S. Danese, L. Peyrin-Biroulet, T. Hibi,
Ulcerative colitis, Nat Rev Dis Primers 6(1) (2020) 74.
[21] R.P. Hirten, B.E. Sands, New Therapeutics for Ulcerative
Colitis, Annu Rev Med 72 (2021) 199-213.
[22] R.P.D. Nascimento, A. Machado, J. Galvez, C.B.B. Cazarin, M.R.
Marostica Junior, Ulcerative colitis: Gut microbiota, immunopathogenesis
and application of natural products in animal models, Life Sci 258
(2020) 118129.
[23] N. Kelley, D. Jeltema, Y. Duan, Y. He, The NLRP3 Inflammasome:
An Overview of Mechanisms of Activation and Regulation, Int J Mol Sci
20(13) (2019).